Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients: a Single-arm, Multicenter, Phase II Clinical Trial（Rocket Trial）

NCT06647940 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06647940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06647940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients: a Single-arm, Multicenter, Phase II Clinical Trial（Rocket Trial）
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2024
Completion date
March 1, 2027
Enrollment
39 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl)